# US 2020/0206351 A1 · Local anesthetic solution for dental and/or contrast media use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206351 A1
- Document ID: US20200206351A1
- Status: Published application
- Kind: A1
- Application number: 16/545,263
- Filed: 2019-08-20
- Published: 2020-07-02
- Earliest claimed: 2014-01-01
- Assignees: Real Time Imaging Technologies, LLC
- Applicants: Real Time Imaging Technologies, LLC
- Inventors: Daniel UZBELGER FELDMAN
- Web page: https://patentgrep.com/patent/US20200206351A1

## CPC

- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61B 6/032: {Transmission computed tomography [CT]}
- A61B 6/481: {involving the use of contrast agents}
- A61B 6/485: {involving fluorescence X-ray imaging}
- A61B 6/51: for dentistry
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0063: {Periodont}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/245: Amino benzoic acid types, e.g. procaine, novocaine (salicylic acid esters A61K31/60)
- A61K 31/381: having five-membered rings
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 49/04: X-ray contrast preparations
- A61M 5/007: {for contrast media}
- A61M 5/14: Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M 5/178: Syringes
- A61M 11/00: Sprayers or atomisers specially adapted for therapeutic purposes (in general B05B; {aerosol containers B65D83/14})
- A61P 23/02: Local anaesthetics
- A61M 2202/048: Anaesthetics
- A61M 2210/0618: Nose
- A61M 2210/0625: Mouth
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An improved local anesthetic solution with diminished bitter taste includes an anesthetic agent, an anesthetic solution vehicle, and a bitterness suppressant. The bitterness suppressant includes one or more compounds selected from the group consisting of: a sugar selected from the group consisting of monosaccharide sugars, disaccharide sugars, polysaccharide sugars, and combinations of the any of the foregoing; sweet-tasting compounds; acids; amino acids; salts; miscellaneous suppressant substances; and combinations of any of the foregoing. The improved local anesthetic solution optionally includes one or more additional agents selected from the group consisting of: buffering agents; vasoconstrictors; preservative compounds; stabilizers; contrast media agents; and combinations of any of the foregoing.

## Claims

### Claim at position 1

-36. (canceled)

### Claim 37

A local anesthetic solution for dental treatment comprising:
an anesthetic agent;
a bitterness suppressant that includes an amino acid and at least one of dextrose, fructose, sucrose, and saccharin;
a buffering agent that includes a lactated Ringer's solution;
a stabilizer that includes lecithin or sodium hydroxide; and
an anesthetic solution vehicle in an aqueous form or hydrogel form;
wherein the amino acid includes at least one of arginine, glycine, and glutamic acid.

### Claim 38 (depends on 37)

The local anesthetic solution of claim 37, wherein the anesthetic agent includes one or more anesthetic agents selected from the group consisting of: lidocaine; tetracaine; mepivacaine; prilocaine; bupivacaine; etidocaine; ropivacaine; and articaine.

### Claim 39 (depends on 37)

The local anesthetic solution of claim 37, further comprising one or more vasoconstrictors selected from the group consisting of: adrenaline; epinephrine; norepinephrine; phenylephrine; felypressin; and levonordefrin.

### Claim 40 (depends on 37)

The local anesthetic solution of claim 37, further comprising one or more preservative compounds selected from the group consisting of: a paraben; sodium bisulfites or metabisulfites; ascorbic acid; and benzyl alcohol.

### Claim 41 (depends on 37)

The local anesthetic solution of claim 37, further comprising one or more contrast media agents for enabling visualization of the solution using x-ray technology, wherein the one or more contrast media agents are selected from the group consisting of: ionic iodine; non-ionic iodine; sodium iodide; sodium iothalamate; iron; iron oxide; iron platinum; manganese; perflubron; nitrogen; and perfluorocarbon.

### Claim 42

A local anesthetic solution for dental treatment comprising:
an anesthetic agent;
a bitterness suppressant that includes an amino acid and at least one of dextrose, fructose, sucrose, and saccharin;
a buffering agent;
a stabilizer; and
an anesthetic solution vehicle in an aqueous form or hydrogel form.

### Claim 43 (depends on 42)

The local anesthetic solution of claim 42, wherein the anesthetic agent includes one or more anesthetic agents selected from the group consisting of: lidocaine; tetracaine; mepivacaine; prilocaine; bupivacaine; etidocaine; ropivacaine; and articaine.

### Claim 44 (depends on 42)

The local anesthetic solution of claim 42, wherein the buffering agent includes one or more buffering agents selected from the group consisting of: Hartmann's solution; Ringer's solution; lactated Ringer's solution; acetated Ringer's solution; and bicarbonated Ringer's solution.

### Claim 45 (depends on 42)

The local anesthetic solution of claim 42, wherein the stabilizer includes one or more stabilizers selected from the group consisting of: citric acid, sodium hydroxide; lecithin; fatty acid emulsions; and polysorbate 80.

### Claim 46 (depends on 42)

The local anesthetic solution of claim 42, wherein the bitterness suppressant further includes one or more amino acids selected from the group consisting of: lysine; glutamic acid; leucine; arginine; alanine; valine; isoleucine; aspartic acid; phenylalanine; glycine; serine; histidine; threonine; ornithine monohydrochloride; proline; methionine; tryptophan; cysteine; taurine; and tyrosine.

### Claim 47 (depends on 42)

The local anesthetic solution of claim 42, further comprising one or more vasoconstrictors selected from the group consisting of: adrenaline; epinephrine; norepinephrine; phenylephrine; felypressin; and levonordefrin.

### Claim 48 (depends on 42)

The local anesthetic solution of claim 42, further comprising one or more contrast media agents for enabling visualization of the solution using x-ray technology, wherein the one or more contrast media agents are selected from the group consisting of: ionic iodine; non-ionic iodine; sodium iodide; sodium iothalamate; iron; iron oxide; iron platinum; manganese; perflubron; nitrogen; and perfluorocarbon.

### Claim 49

A local anesthetic solution for dental treatment comprising:
an anesthetic agent;
a bitterness suppressant that includes an amino acid and an artificial sweetener;
a buffering agent;
a stabilizer that includes lecithin or sodium hydroxide; and
an anesthetic solution vehicle in an aqueous form or hydrogel form;
wherein the amino acid includes at least one of arginine, glycine, and glutamic acid.

### Claim 50 (depends on 49)

The local anesthetic solution of claim 49, wherein the artificial sweetener includes one or more artificial sweeteners selected from the group consisting of: saccharin; aspartame; acesulfame potassium; sucralose; neotame; and advantame.

### Claim 51 (depends on 49)

The local anesthetic solution of claim 49, wherein the anesthetic agent includes one or more anesthetic agents selected from the group consisting of: lidocaine; tetracaine; mepivacaine; prilocaine; bupivacaine; etidocaine; ropivacaine; and articaine.

### Claim 52 (depends on 49)

The local anesthetic solution of claim 49, wherein the bitterness suppressant further includes sodium lactate or sodium chloride.

### Claim 53 (depends on 49)

The local anesthetic solution of claim 49, wherein the buffering agent includes one or more buffering agents selected from the group consisting of: Hartmann's solution; Ringer's solution; lactated Ringer's solution; acetated Ringer's solution; and bicarbonated Ringer's solution.

### Claim 54 (depends on 49)

The local anesthetic solution of claim 49, further comprising one or more vasoconstrictors selected from the group consisting of: adrenaline; epinephrine; norepinephrine; phenylephrine; felypressin; and levonordefrin.

### Claim 55 (depends on 49)

The local anesthetic solution of claim 49, further comprising one or more preservative compounds selected from the group consisting of: a paraben; sodium bisulfites or metabisulfites; ascorbic acid; and benzyl alcohol.

### Claim 56 (depends on 49)

The local anesthetic solution of claim 49, further comprising one or more contrast media agents for enabling visualization of the solution using x-ray technology, wherein the one or more contrast media agents are selected from the group consisting of: ionic iodine; non-ionic iodine; sodium iodide; sodium iothalamate; iron; iron oxide; iron platinum; manganese; perflubron; nitrogen; and perfluorocarbon.
